Étiquette : methamphétamine

A Comparative Review of the Neuro- Psychopharmacology of Hallucinogen-Induced Altered States of Consciousness : The Uniqueness of Some Hallucinogens, Ümit Sayin, 2012

A Comparative Review of the Neuro- Psychopharmacology of Hallucinogen-Induced Altered States of Consciousness : The Uniqueness of Some Hallucinogens Ümit Sayin NeuroQuantology, June 2012, Volume 10, Issue 2,  316-340. eISSN 1303-5150   ABSTRACT Altered states of consciousness induced by hallucinogens (H-ASC) is still a vaguely understood phenomenon. Taken the diverse psychological effects they exert, the main mechanism of action of hallucinogens; LSD, ibogaine, THC, PCP, MDMA, methamphetamine, mescaline, psilocybin and DMT, of which psychological effects are discussed in the article, are not properly understood and explained by the modern methods of neuroscience due to the lack of vigorous research. The involvement of some receptors, such as, [...]

Lire la suite

Use of Marijuana, Meth, Hallucinogens Up in New SAMHSA Survey, Damian McNamara, August 2019

Use of Marijuana, Meth, Hallucinogens Up in New SAMHSA Survey Damian McNamara Medscape - Aug 22, 2019 Medscape Medical News © 2019 https://www.medscape.com/viewarticle/917131?nlid=131240_2052&src=WNL_mdplsnews_190823_mscpedit_psyc&uac=292598PZ&spon=12&impID=2070816&faf=1 Almost 1 million more Americans ages 12 or older reported using marijuana in their lifetime in 2018 than in 2017, according to new data from a national survey. The Substance Abuse and Mental Health Services Administration (SAMHSA) 2018 National Survey on Drug Use and Health Report notes that approximately 1.2 million more people reported use of hallucinogens, which include LSD, PCP, and Ecstasy, compared with 2017. In addition, about 170,000 more people used methamphetamine. Not all substance use increased year over year. For example, 187,000 fewer adolescent and adult Americans [...]

Lire la suite

Neurometabolic Effects of Psilocybin, 3,4-Methylenedioxyethylamphetamine (MDE) and d-Meth-amphetamine in Healthy Volunteers. A Double-Blind, Placebo-Controlled PET Study with [18 F] FDG, Euphrosyne Gouzoulis-Mayfrank et al., 1999

Neurometabolic Effects of Psilocybin, 3,4-Methylenedioxyethylamphetamine (MDE) and d-Meth-amphetamine in Healthy Volunteers. A Double-Blind, Placebo-Controlled PET Study with [18 F] FDG Euphrosyne Gouzoulis-Mayfrank, Mathias Schreckenberger, Osama Sabri, Christoph Arning, Bernhard Thelen, Manfred Spitzer, Ph.D., Karl-Artur Kovar, Leopold Hermle,  Udalrich Büll, and Henning Sass. NEUROPSYCHOPHARMACOLOGY, 1999–VOL 20, NO 6, 565-581. PII S0893-133X(98)00089-X   The neurometabolic effects of the hallucinogen psilocybin (PSI; 0.2 mg/kg), the entactogen 3,4- methylenedioxyethylamphetamine (MDE; 2 mg/kg) and the stimulant d-methamphetamine (METH; 0.2–0.4 mg/kg) and the drugs’ interactions with a prefrontal activation task were investigated in a double-blind, placebo-controlled human [F-18]fluorodeoxyglucoseFDG-positron emission tomographicPET study (each group: n 5 8). Subjects underwent two scans (control: [...]

Lire la suite

Cannabidiol inhibits priming-induced reinstatement of methamphetamine in REM sleep deprived rats Saeideh Karimi-Haghighi, Abbas Haghparast, 2017

Cannabidiol inhibits priming-induced reinstatement of methamphetamine in REM sleep deprived rats Saeideh Karimi-Haghighi, Abbas Haghparast Neuroscience Research Center, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran Progress in Neuropsychopharmacology & Biological Psychiatry, 2017. http://dx.doi.org/10.1016/j.pnpbp.2017.08.022   A B S T R A C T Methamphetamine (METH) is a widely abused and a severely addictive psychostimulant. Relapse is the main cause of concern when treating addiction. It could manifest after a long period of abstinence. Previous studies showed that there is a strong connection between sleep impairment and relapse. Also, it has been reported that cannabidiol might be a potential treatment for drug craving and relapse. [...]

Lire la suite

Cannabidiol treatment reduces the motivation to self-administer methamphetamine and methamphetamine-primed relapse in rats, Gracie L. Hay et al., 2018

Cannabidiol treatment reduces the motivation to self-administer methamphetamine and methamphetamine-primed relapse in rats Gracie L. Hay, Sarah J. Baracz, Nicholas A. Everett, Jessica Roberts, Priscila A. Costa, Jonathon C. Arnold, Iain S. McGregor and Jennifer L. Cornish Journal of Psychopharmacology, 2018, 32, (12), 1369-1378. DOI : 10.1177/0269881118799954 ,  journals.sagepub.com/home/jop   Abstract Background : Methamphetamine is an addictive stimulant that can cause many adverse physical, psychological and psychosocial effects. Preliminary evidence shows cannabidiol, a non-intoxicating constituent of the cannabis plant, may have efficacy in treating opioid and nicotine dependence. However, no study has yet examined whether cannabidiol treatment might impact on methamphetamine addiction. Aims : The current study [...]

Lire la suite